HDAC9 and cancer: To date, five HDAC inhibitors have been approved for cancer treatment-vorinostat and romidepsin to treat refractory cutaneous T-cell lymphoma [22,23], panobinostat for patients with multiple myeloma [24], plus belinostat and chidamide for the treatment of relapsed or refractory peripheral T-cell lymphoma [25,26].